InnoSer Partnership Press Release

Early 2021, Belgian headquartered preclinical contract research organization (CRO) InnoSer gathered its brands under the umbrella of InnoSer International BV, also adding C-Path for preclinical and clinical pathology services as a new company in the group. The close partnership formed between InnoSer and C-Path enables fully integrated and world-class pathological assessments in InnoSer’s preclinical drug development pipelines.

InnoSer’s Managing Director Jan Bartels says: “Pathology was already an integral part of our oncology and nephrology studies. Now, with pathology expertise assembled in C-Path, we bring this offering to the next level. Everything we do is to better serve our customers and a close partnership between InnoSer and C-Path ensures seamless integration of our various services.”

C-path not only brings preclinical and clinical pathology experts together, but it also leverages smart technologies for process automation and data streamlining. InnoSer’s CTO Wim Tiest explains: “Pathologists are scarce resources. A workflow aided by digital track and trace of samples helps our pathologists focus on valuable decision-making.” Digital pathology services offer InnoSer’s customers a way to accelerate their drug development.

About InnoSer

Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting discovery and preclinical development of drugs. InnoSer’s offerings include a proprietary PDX/O screening platform for oncology, a unique ADPKD mouse model for nephrology, and a fully characterized midbrain organoid model for Parkinson’s disease. InnoSer also provides in vivo imaging, pathology and genetically engineered mouse model services including colony management, cryopreservation, and sanitation/rederivation.

About C-Path

Founded in 2021, C-Path, or Connected-Pathology, provides a full suite of preclinical and clinical pathology solutions. These include conventional pathology, molecular pathology, laboratory animal pathology, and preclinical safety and efficacy, as well as clinical consulting, AI pathology, digital sample tracking, and data management.

For more information, please contact:
Jan Bartels, Managing Director

= This press release was originally published at InnoSer’s news pages. =